Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phasen III, randomized, double-blind, placebo-controlled study

摘要

Background. Pruritus in haemodialysis patients is an intractable disease and substantially impairs their quality of life. Based on the results of our earlier clinical study, we hypothesized that the μ-(mu) opioid system is itch-inducible, whereas the κ (kappa) system is itch-suppressive.